Literature DB >> 3342372

Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation.

D X Qin1, Y H Hu, J H Yan, G Z Xu, W M Cai, X L Wu, D X Cao, X Z Gu.   

Abstract

One thousand three hundred seventy-nine nasopharyngeal carcinoma (NPC) patients were treated from March 1958 to December 1978. Twenty-two percent had stage I or II and 78% Stage III or IV had lesions. Two hundred twenty-Kv radiographs were used before 1960; and telecobalt was used from 1961 to 1978. Factors influencing the 5-year survival rate favorably are youth of patient, being female, pathologic condition (poorly differentiated carcinoma, 45.1% versus adenocarcinoma, 13%), stage (Stage I, 86%, Stage II, 59.5%; Stage III, 45.8%; Stage IV, 29.2%), decade admitted for treatment in the past (31% in the 1950s, 48.6% in the 1970s), total dose delivered to the nasopharynx (40 to 49 Gy, 46%; 70 to 79 Gy, 54.1%; 90 Gy or more, 64%) and prophylactic radiation to the neck regions (with prophylactic irradiation, 53.8%, without prophylactic irradiation, 23%). This implies that prophylactic radiation of the neck is crucial even without positive clinical metastasis. For those who have a residual tumor in the primary site when 70 Gy has been delivered, the total dose may be boosted to more than 90 Gy with the cone-down technique or on basis of adding 20 Gy to the dose at which the primary lesion disappeared grossly. The common postirradiation complications are: radiation myelitis, trismus, and otitis media. Because disease recurred in some patients after the fifth year, NPC patients should be followed for at least 10 years.

Entities:  

Mesh:

Year:  1988        PMID: 3342372     DOI: 10.1002/1097-0142(19880315)61:6<1117::aid-cncr2820610611>3.0.co;2-j

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  24 in total

Review 1.  Nasopharyngeal carcinoma.

Authors:  Muhyi Al-Sarraf; Maryada S Reddy
Journal:  Curr Treat Options Oncol       Date:  2002-02

2.  Radiation-induced cranial neuropathy in patients with nasopharyngeal carcinoma. A follow-up study.

Authors:  X Rong; Y Tang; M Chen; K Lu; Y Peng
Journal:  Strahlenther Onkol       Date:  2012-03       Impact factor: 3.621

3.  Pathobiology of selected tumors of the base of the skull.

Authors:  L Barnes
Journal:  Skull Base Surg       Date:  1991

Review 4.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

5.  Post-treatment late complications of nasopharyngeal carcinoma.

Authors:  Cheng-Chang Lee; Ching-Yin Ho
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-01-15       Impact factor: 2.503

6.  A new T staging system for nasopharyngeal carcinoma based on intensity-modulated radiation therapy: results from a prospective multicentric clinical study.

Authors:  Min Kang; Pingting Zhou; Tingting Wei; Tingting Zhao; Jianxiong Long; Guisheng Li; Haolin Yan; Guosheng Feng; Meilian Liu; Jinxian Zhu; Rensheng Wang
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 7.  Contribution of radiotherapy to function preservation and cancer outcome in primary treatment of nasopharyngeal carcinoma.

Authors:  Anne W M Lee
Journal:  World J Surg       Date:  2003-07       Impact factor: 3.352

Review 8.  Locally advanced nasopharyngeal cancer.

Authors:  J F Ensley; E Youssef; H Kim; G Yoo
Journal:  Curr Treat Options Oncol       Date:  2001-02

9.  MRI findings in patients with severe trismus following radiotherapy for nasopharyngeal carcinoma.

Authors:  Kunwar S S Bhatia; Ann D King; Bhawan K Paunipagar; Jill Abrigo; Alexander C Vlantis; Sing F Leung; Anil T Ahuja
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

10.  Treatment outcome of cisplatin-based concurrent chemoradiotherapy in the patients with locally advanced nasopharyngeal cancer.

Authors:  Tae Hee Kim; Yoon Ho Ko; Myung Ah Lee; Bum-soo Kim; So Ryoung Chung; Ie Ryung Yoo; Chan-Kwon Jung; Yeon-Sil Kim; Min Sik Kim; Dong-Il Sun; Young Seon Hong; Kyung Shik Lee; Jin-Hyoung Kang
Journal:  Cancer Res Treat       Date:  2008-06-30       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.